Preconception hemoglobin A1c concentration in healthy women is not associated with fecundability or pregnancy loss

Jessica R Zolton, Lindsey A Sjaarda, Sunni L Mumford, Tiffany L Holland, Keewan Kim, Kerry S Flannagan, Samrawit F Yisahak, Stefanie N Hinkle, Matthew T Connell, Mark V White, Neil J Perkins, Robert M Silver, Micah J Hill, Alan H DeCherney, Enrique F Schisterman, Jessica R Zolton, Lindsey A Sjaarda, Sunni L Mumford, Tiffany L Holland, Keewan Kim, Kerry S Flannagan, Samrawit F Yisahak, Stefanie N Hinkle, Matthew T Connell, Mark V White, Neil J Perkins, Robert M Silver, Micah J Hill, Alan H DeCherney, Enrique F Schisterman

Abstract

Objective: To examine the relationship of preconception hemoglobin A1c, a marker of cumulative exposure to glucose over the preceding 2-3 months, with time to pregnancy, pregnancy loss, and live birth among fecund women without diagnosed diabetes or other medical diseases.

Design: A secondary analysis of a prospective cohort of women participating in the Effects of Aspirin in Gestation and Reproduction (EAGeR) trial.

Setting: Four US academic medical centers.

Patients: A total of 1,194 healthy women aged 18-40 years with a history of one or two pregnancy losses attempting spontaneous conception were observed for up to six cycles while attempting pregnancy and throughout pregnancy if they conceived.

Interventions: Not applicable.

Main outcome measures: Time to pregnancy, human chorionic gonadotropin pregnancy, clinical pregnancy, pregnancy loss, and live birth.

Results: Although increasing preconception A1c level was associated with reduced fecundability (fecundability odds ratio [FOR] per unit increase in A1c 0.74; 95% confidence interval [CI] 0.57, 0.96) in unadjusted models and models adjusted for age, race, smoking and treatment arm (FOR 0.79; 95% CI 0.60, 1.04), results were attenuated after further adjustment for body mass index (FOR 0.91; 95% CI 0.68, 1.21). Preconception A1c levels among women without diagnosed diabetes were not associated with live birth or pregnancy loss.

Conclusionss: Among healthy women without diagnosed diabetes, we observed no association of A1c with live birth or pregnancy loss. The association between A1c and fecundability was influenced by body mass index, a strong risk factor for both diabetes and infertility. These data support current recommendations that preconception A1c screening should be reserved for patients with risk factors for diabetes.

Clinical trial registration number: ClinicalTrials.gov: NCT00467363.

Keywords: fecundability; hemoglobin A1c; preconception care; pregnancy loss.

© 2022 Published by Elsevier Inc. on behalf of American Society for Reproductive Medicine.

References

    1. American Diabetes Association 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–S27.
    1. Mills J.L., Simpson J.L., Driscoll S.G., Jovanovic-Peterson L., Van Allen M., Aarons J.H., et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med. 1988;319:1617–1623.
    1. Jensen D.M., Korsholm L., Ovesen P., Beck-Nielsen H., Moelsted-Pedersen L., Westergaard J.G., et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009;32:1046–1048.
    1. Mills J.L. Malformations in infants of diabetic mothers. Teratology. 1982;25:385–394.
    1. Lesseur C., Chen J. Adverse maternal metabolic intrauterine environment and placental epigenetics: implications for fetal metabolic programming. Curr Environ Health Rep. 2018;5:531–543.
    1. Fraser R.B., Waite S.L., Wood K.A., Martin K.L. Impact of hyperglycemia on early embryo development and embryopathy: in vitro experiments using a mouse model. Hum Reprod. 2007;22:3059–3068.
    1. Cawyer C.R., Horvat D., Leonard D., Allen S.R., Jones R.O., Zawieja D.C., et al. Hyperglycemia impairs cytotrophoblast function via stress signaling. Am J Obstet Gynecol. 2014;211:541.e1–541.e8.
    1. Practice Committee of the American Society for Reproductive Medicine Evaluation and treatment of recurrent pregnancy loss: a committee opinion. Fertil Steril. 2012;98:1103–1111.
    1. Zinaman M.J., Clegg E.D., Brown C.C., O'Connor J., Selevan S.G. Estimates of human fertility and pregnancy loss. Fertil Steril. 1996;65:503–509.
    1. Chandra A., Copen C.E., Stephen E.H. Infertility and impaired fecundity in the United States, 1982–2010: data from the National Survey of Family Growth. Natl Health Stat Report. 2013;67:1–18. 1 p following 9.
    1. Wei H.J., Young R., Kuo I.L., Liaw C.M., Chiang H.S., Yeh C.Y. Abnormal preconception oral glucose tolerance test predicts an unfavorable pregnancy outcome after an in vitro fertilization cycle. Fertil Steril. 2008;90:613–618.
    1. Wei D., Zhang B., Shi Y., Zhang L., Zhao S., Du Y., et al. Effect of preconception impaired glucose tolerance on pregnancy outcomes in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102:3822–3829.
    1. Zhao J., Hong X., Zhang H., Dai Q., Huang K., Zhang X., et al. Pre-pregnancy maternal fasting plasma glucose levels in relation to time to pregnancy among the couples attempting first pregnancy. Hum Reprod. 2019;34:1325–1333.
    1. Sacks D.B. A1C versus glucose testing: a comparison. Diabetes Care. 2011;34:518–523.
    1. Schisterman E.F., Silver R.M., Perkins N.J., Mumford S.L., Whitcomb B.W., Stanford J.B., et al. A randomised trial to evaluate the effects of low-dose aspirin in gestation and reproduction: design and baseline characteristics. Paediatr Perinat Epidemiol. 2013;27:598–609.
    1. Craig C.L., Marshall A.L., Sjostrom M., Bauman A.E., Booth M.L., Ainsworth B.E., et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exer. 2003;35:1381–1395.
    1. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–419.
    1. American Diabetes Association Standards of medical care in diabetes-2018 abridged for primary care providers. Clin Diabetes. 2018;36:14–37.
    1. Welsh C., Welsh P., Celis-Morales C.A., Mark P.B., Mackay D., Ghouri N., et al. Glycated hemoglobin, prediabetes, and the links to cardiovascular disease: data from UK Biobank. Diabetes Care. 2020;43:440–445.
    1. Selvin E., Steffes M.W., Zhu H., Matsushita K., Wagenknecht L., Pankow J., et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. N Engl J Med. 2010;362:800–811.
    1. Mann D.M., Carson A.P., Shimbo D., Fonseca V., Fox C.S., Muntner P. Impact of A1C screening criterion on the diagnosis of pre-diabetes among US adults. Diabetes Care. 2010;33:2190–2195.
    1. Jungheim E.S., Travieso J.L., Carson K.R., Moley K.H. Obesity and reproductive function. Obstet Gynecol Clin North Am. 2012;39:479–493.
    1. Sundaram R., Mumford S.L., Buck Louis G.M. Couples' body composition and time-to-pregnancy. Hum Reprod. 2017;32:662–668.
    1. Tian L., Shen H., Lu Q., Norman R.J., Wang J. Insulin resistance increases the risk of spontaneous abortion after assisted reproduction technology treatment. J Clin Endocrinol Metab. 2007;92:1430–1433.
    1. Jakubowicz D.J., Seppala M., Jakubowicz S., Rodriguez-Armas O., Rivas-Santiago A., Koistinen H., et al. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:1126–1133.
    1. Wu Y., Wang F., Fu M., Wang C., Quon M.J., Yang P. Cellular stress, excessive apoptosis, and the effect of metformin in a mouse model of type 2 diabetic embryopathy. Diabetes. 2015;64:2526–2536.
    1. Schulte M.M., Tsai J.H., Moley K.H. Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation. Reprod Sci. 2015;22:6–14.
    1. Wei Y., Xu Q., Yang H., Yang Y., Wang L., Chen H., et al. Preconception diabetes mellitus and adverse pregnancy outcomes in over 6.4 million women: a population-based cohort study in China. PLoS Med. 2019;16
    1. Lowe L.P., Metzger B.E., Dyer A.R., Lowe J., McCance D.R., Lappin T.R., et al. Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study: associations of maternal A1C and glucose with pregnancy outcomes. Diabetes Care. 2012;35:574–580.
    1. Mane L., Flores-Le Roux J.A., Benaiges D., Rodriguez M., Marcelo I., Chillaron J.J., et al. Role of first-trimester HbA1c as a predictor of adverse obstetric outcomes in a multiethnic cohort. J Clin Endocrinol Metab. 2017;102:390–397.
    1. Hughes R.C.E., Williman J.A., Gullam J.E. Antenatal haemoglobin A1c centiles: does one size fit all? Aust N Z J Obstet Gynaecol. 2018;58:411–416.
    1. O'Connor C., O'Shea P.M., Owens L.A., Carmody L., Avalos G., Nestor L., et al. Trimester-specific reference intervals for haemoglobin A1c (HbA1c) in pregnancy. Clin Chem Lab Med. 2011;50:905–909.
    1. Nielsen G.L., Moller M., Sorensen H.T. HbA1c in early diabetic pregnancy and pregnancy outcomes: a Danish population-based cohort study of 573 pregnancies in women with type 1 diabetes. Diabetes Care. 2006;29:2612–2616.
    1. Khalafallah A., Phuah E., Al-Barazan A.M., Nikakis I., Radford A., Clarkson W., et al. Glycosylated haemoglobin for screening and diagnosis of gestational diabetes mellitus. BMJ Open. 2016;6
    1. Hughes R.C., Moore M.P., Gullam J.E., Mohamed K., Rowan J. An early pregnancy HbA1c ≥5.9% (41 mmol/mol) is optimal for detecting diabetes and identifies women at increased risk of adverse pregnancy outcomes. Diabetes Care. 2014;37:2953–2959.
    1. Fong A., Serra A.E., Gabby L., Wing D.A., Berkowitz K.M. Use of hemoglobin A1c as an early predictor of gestational diabetes mellitus. Am J Obstet Gynecol. 2014;211:641.e1–641.e7.
    1. Radin M.S. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014;29:388–394.
    1. Sacks D.B., John W.G. Interpretation of hemoglobin A1c values. JAMA. 2014;311:2271–2272.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi